CTOs on the Move

Innovative Cellular Therapeutics

www.ictbio.com

 
Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ictbio.com
  • 1405 Research Boulevard Suite 210
    Rockville, MD USA 20850
  • Phone: 240.690.9110

Executives

Name Title Contact Details

Similar Companies

Avecia Biotechnology

Avecia Biotechnology is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DM Clinical Research

DM Clinical Research is a clinical research company that connects pharmaceutical and research organizations to individuals seeking to power the advancement of medicine. They specialize in multiple therapeutic areas in Phase I-IV clinical trials.

Nostrum Laboratories

Nostrum Laboratories is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enveric Biosciences

Enveric Biosciences is a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of cancer treatments. Enveric Biosciences has set out with the goal of rigorously testing natural compounds, starting with cannabinoids, to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs.

Trefoil Therapeutics

Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.